Zhongchao Inc. Launches Medication Management Assistance Mini Program to Facilitate Cancer Treatment

20 January 2023 | Friday | News

Zhongchao Inc. (NASDAQ: ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced that Zhongxin Medical Technology Co., Ltd. ("Zhongxin"), one of the China operating entities of which the Company consolidates the financial results with through certain contractual arrangements, launched the Medication Management Assistance Mini Program on WeChat (the "Program") to assist cancer patients in managing multiple issues during the medication and facilitate whole treatment process.
Image Source : Public Domain

Image Source : Public Domain

Zhongxin launched the Program aiming to navigate and solve the medication challenges faced by cancer patients. During cancer treatment process, the use of one or more anti-tumor drugs, especially targeted and immune drugs, will face various challenges, including, among others, dosing punctuality, incorrect dosage, missed dose, taking with other drugs and adverse reaction management. If such challenges cannot be solved, the treatment process will be negatively affected, and patients' confidence in treatment could be undermined, ultimately affecting the curative effect.

In order to resolve medication-related challenges in a timely manner and promote the continuity of treatment, Zhongxin developed and designed the Program with several functions. The Program can automatically remind patients to take medication and precautions according to the characteristics of different cancers and consumption time of medications. It can also provide general self-treatment information based on the adverse reactions that patients might have taking such medications and timely provide corresponding self-treatment information for such adverse reactions specifically encountered by patients during the medication administration process. Additionally, the Program could train patients' self-management ability through various illustrations and video courses.

Through the Program, patients can choose different types of cancers and corresponding drugs to customize and self-manage their medication process, and such convenience could boost patients' confidence in their cancer treatment. Currently, the Program only targets patients with lung cancer and kidney cancer, and Zhongxin plans to expand to cover other cancers in the future.

Weiguang Yang, Chairman and Chief Executive Officer of Zhongchao, commented, "we are excited about the launch of the Program. As cancer treatment technology, drugs and solutions advance, patient-side knowledge and behaviors are increasingly important during treatment process and have positive effects on cancer treatment, we believe that by cultivating good medication habits for patients and providing assistance to patients, it will achieve maximum efficacy and improve cancer treatment outcomes. We expect that the Program will further enhance patient service experience and increase user loyalty. Going forward, we will continue to improve our services offering to better pursue our goal of contributing to improved cancer patient treatment experience and outcomes."


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in